P-70 HEPATITIS B IMMUNITY AMONG CHRONIC RENAL DISEASE UNDER HEMODIALYSIS

Santos, Alanna Calheiros; Melgaço, Juliana Gil; da Silva, Lucas Lima; da Costa, Vanessa Duarte; Miguel, Juliana Custódio; da Silva, Elisangela Ferreira; Marques, Julia Trece; Prado do Nascimento, Giselle; de Paula, Vanessa Salete; Villar, Livia Melo

doi:10.1016/j.aohep.2023.100967

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Web of Science, Medline/PubMed, DOAJ and Conacyt

Hepatitis B Virus (HBV) has been a cause of acute and chronic hepatitis with progression to cirrhosis and hepatocellular carcinoma. Individuals with chronic kidney disease (CKD) are especially susceptible to HBV infection. Some studies have shown high rates of positivity for the HBV infection marker in this population and therefore, vaccination becomes a safe method for Hepatitis B prevention. CKD patients are generally immunosuppressed and have a lower response to the Hepatitis B vaccine when compared to healthy individuals. Some factors associated with vaccine non-response are older age and immunosuppression. This study aimed to evaluate the humoral immune response through the titration of antibodies against HBsAg (anti-HBs) after hepatitis B vaccination in chronic renal disease patients.

Material and Methods

This is a cross sectional study conducted in two hemodialysis units serving individuals with CKD in Rio de Janeiro State, where 98 patients were included. All of them consented to participate and donated blood samples. All individuals have fulfilled a questionnaire about demographic characteristics, including information about previous HBV vaccination. Serum samples were tested for anti-HBSs employing chemiluminescent immunoassay (CLIA) technology with the commercial kit (LIAISON®XL, DiaSorin).

Results

Among 98 patients studied so far, the mean age was 51.9 years, 54/98 (56.8) female. With regard to the presence of anti-HBs, 56/98 (57.1%) individuals tested positive. Among those individuals, 45 had taken at least one dose of the hepatitis B vaccine. On the other hand, 9/42 (21,4%) seronegative patients all reported having taken the hepatitis B vaccine.

Conclusions

The vaccine remains the best and most effective method of preventing and controlling hepatitis B. This study demonstrated low HBV immunity in this population, reinforcing the need for four-dose booster schedules for this population. In addition, host factors should be investigated in non-responder to the vaccine.

Full text is only aviable in PDF

Indexed in:

Follow us:

Subscribe to our newsletter